

PHARMING TO PRESENT AT BIO-EUROPE 2009

Leiden, The Netherlands, October 26, 2009. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) today announced that it will present at the 15th BIO-Europe (November 2-4, 2009) in Vienna, Austria.

Sijmen de Vries, Chief Executive Officer of Pharming, will present an update of the Company and its business at the BIO-Europe conference on Tuesday, November 3 at 11:00 am Central European Time. BIO-Europe is Europe's largest international partnering conference. The conference attendees include delegates from Europe, North America and Asia-Pacific. For further information on the BIO-Europe 2009, please visit <http://www.ebdgroup.com/bioeurope>.

The presentation will be available on Pharming's website after the meeting.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. Pharming's lead product Rhucin® for acute attacks of Hereditary Angioedema has passed clinical development stage and the Market Authorization Application is under review with EMEA. Prodarsan® is in early stage clinical development for Cockayne Syndrome and lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, <http://www.pharming.com>.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact:

Ms. Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54